QUANTOSE® IGT is a laboratory-developed test (LDT) that reflects the degree of impaired glucose tolerance (IGT) in an individual - a known risk factor for prediabetes and cardiovascular disease. Prediabetes occurs when blood glucose levels that are higher than normal, but not yet high enough to be diagnosed as diabetes. Our test is designed to easily differentiate IGT from normal glucose tolerance. Quantose® IGT is currently available to clinicians in the U.S.

Quantose® IGT is the first convenient test developed and clinically validated using the gold standard for impaired glucose tolerance, the oral glucose tolerance test (OGTT). We offer a simplified OGTT process that requires only a single, fasted blood draw.

According to the Centers for Disease Control (CDC), about 86 million Americans have prediabetes, and nine out of 10 are undiagnosed. The International Diabetes Federation puts the number at about 344 million people globally. About half the adults with IGT are under the age of 50.

  • IGT is a prediabetic state at high risk for the development of type 2 diabetes and cardiovascular disease.1
  • Patients with both IGT and impaired fasting glucose (IFG) are twice as likely to develop type 2 diabetes compared to patients who are either IGT or IFG.2
  • IGT is a stronger predictor for cardiovascular disease over IFG.2,3


  • Overweight or obese
  • Family history of type 2 diabetes
  • Little physical activity
  • Have hypertension or high cholesterol
  • History of Gestational diabetes
  • Increasing age
  • A Quantose® IGT Score is generated using a proprietary algorithm that combines glucose and seven biomarkers associated with dysglycemia, including α-hydroxybutyrate (AHB), oleic acid and linoleoyl-glycerophospocholine (LGPC).
    • α-Hydroxybutyrate (AHB) – an organic acid that may be a marker of fatty acid oxidation and antioxidant glutathione synthesis (oxidative stress)
    • Linoleoyl-glycerophosphocholine (LGPC) – a lipid that may be a marker of fatty acid synthesis in the liver and inflammation
    • Oleic acid – a free fatty acid that is a marker of lipolysis and total plasma fatty acids
    • AHB, LGPC, and oleic acid are selective biomarkers of IGT independent of age, sex, BMI, and fasting glucose.4
  • In patients with insulin resistance and elevated glucose, Quantose® IGT can be used to assess whether they also have impaired glucose tolerance, which places them at higher risk for diabetes.
  • Patients who have been placed on weight-loss treatment may have follow-up testing conducted once the patient’s weight has stabilized.
  • Frequency of testing is at the clinician’s discretion.
  • Quantose® IGT has been clinically developed and validated using the oral glucose tolerance test (OGTT), the gold standard for measuring impaired glucose tolerance. Our test offers a simplified process that requires only a single, fasted blood draw.
  • Historically, the oral glucose tolerance test (OGTT) was the only method to diagnose patients with impaired glucose tolerance. Although IGT is a known risk factor, use of the OGTT has diminished considerably in recent years as it is time-consuming, expensive and unpopular with both patients and physicians.

QUANTOSE IGT is available as a laboratory-developed (LDT) test in the U.S. If you are a healthcare provider and need more information about the test or to order, please contact us at QuantoseIR@metabolon.com or 1.844.IR.FIRST (1.844.473.4778).

1Cobb J, et al. J. Diabetes Science & Technology 2015. 9(1):69-76.
2Nathan D. et al. Diabetes Care. March 2007. 30(3):753-759.
3Lind M. et al. PLoS One. Oct 2014. 9(10):e109506.
4 Cobb, J et al. Diabetes Care 2016. 39(6):988